Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina

被引:2
|
作者
Trogdon, Justin G. [1 ]
Shafer, Paul [1 ]
Lindsay, Brianna [2 ]
Coyne-Beasley, Tamera [3 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101 McGavran Greenberg Hall,Campus Box 7411, Chapel Hill, NC 27599 USA
[2] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA
[3] Univ N Carolina, Dept Pediat, 260 MacNider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA
关键词
Human papillomavirus; Vaccination; Interrupted time series; AGED; 13-17; YEARS; COST-EFFECTIVENESS; UNITED-STATES; ADVISORY-COMMITTEE; HPV VACCINATION; CERVICAL-CANCER; POLIO ENDGAME; RECOMMENDATIONS; HEALTH;
D O I
10.1016/j.vaccine.2018.01.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The objective of this study was to evaluate the impact of introduction of 9vHPV vaccine on HPV vaccination uptake (doses per capita) and initiation (>= 1 doses), completion (>= 3 doses) and compliance (>= 3 doses within 12 months) by adolescents. Methods: We used a retrospective cohort analysis using North Carolina Immunization Registry (NCIR) data from January 2008 through October 2016. The sample included Vaccines for Children eligible adolescents aged 9 to 17 years in 2016, for whom the NCIR contains complete vaccination history. We applied an interrupted time series design to measure associations between ZIP Code Tabulation Area (ZCTA)-level HPV vaccination outcomes over time with the introduction of 9vHPV in North Carolina (NC) in July 2015. Results: Each outcome displayed a linear upward trend over time with large seasonal spikes near August of each year, corresponding to the time when adolescents often receive other vaccines required for school entry. After accounting for these underlying trends, introduction of 9vHPV was not associated with a change in publicly funded HPV vaccination rates in NC. Conclusions: Our results indicate that 9vHPV substituted for 4vHPV in the first year after release in NC, but the release of 9vHPV was not associated with an overall change in HPV vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1304 / 1309
页数:6
相关论文
共 50 条
  • [21] Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population
    Shing, Jaimie Z.
    Griffin, Marie R.
    Chang, Rachel S.
    Beeghly-Fadiel, Alicia
    Sudenga, Staci L.
    Slaughter, James C.
    Pemmaraju, Manideepthi
    Mitchel, Edward F.
    Hull, Pamela C.
    AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2022, 62 (03) : 395 - 403
  • [22] Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine
    Donahue, James G.
    Kieke, Burney A.
    Lewis, Edwin M.
    Weintraub, Eric S.
    Hanson, Kayla E.
    McClure, David L.
    Vickers, Elizabeth R.
    Gee, Julianne
    Daley, Matthew F.
    DeStefano, Frank
    Hechter, Rulin C.
    Jackson, Lisa A.
    Klein, Nicola P.
    Naleway, Allison L.
    Nelson, Jennifer C.
    Belongia, Edward A.
    PEDIATRICS, 2019, 144 (06)
  • [23] Cost-effectiveness analysis of 9-valent human papillomavirus vaccine combined with screening for cervical cancer in Japan
    Takamoto, Naohiro
    Aso, Shotaro
    Ishida, Risa
    Konishi, Takaaki
    Fushimi, Kiyohide
    Yasunaga, Hideo
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024,
  • [24] Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women
    Maria Ruiz-Sternberg, Angela
    Moreira, Edson D., Jr.
    Restrepo, Jaime A.
    Lazcano-Ponce, Eduardo
    Cabello, Robinson
    Silva, Arnaldo
    Andrade, Rosires
    Revollo, Francisco
    Uscanga, Santos
    Victoria, Alejandro
    Maria Guevara, Ana
    Luna, Joaquin
    Plata, Manuel
    Nossa Dominguez, Claudia
    Fedrizzi, Edison
    Suarez, Eugenio
    Reina, Julio C.
    Ellison, Misoo C.
    Moeller, Erin
    Ritter, Michael
    Shields, Christine
    Cashat, Miguel
    Perez, Gonzalo
    Luxembourg, Alain
    PAPILLOMAVIRUS RESEARCH, 2018, 5 : 63 - 74
  • [25] Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
    Ding, Yuan
    Fu, Tingbo
    Zhou, Wenbin
    Zhang, Xiaobo
    Wang, Ruying
    Liao, Huiying
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [26] Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
    Cheung, Tak Hong
    Cheng, Sally Shuk Yee
    Hsu, Danny
    Wing-Lei Wong, Queenie
    Pavelyev, Andrew
    Sukarom, Isaya
    Saxena, Kunal
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)
  • [27] Safety of 9-valent human papillomavirus vaccine administration among pregnant women: Adverse event reports in the Vaccine Adverse Event Reporting System (VAERS), 2014-2017
    Landazabal, Claudia S.
    Moro, Pedro L.
    Lewis, Paige
    Omer, Saad B.
    VACCINE, 2019, 37 (09) : 1229 - 1234
  • [28] Development and Validation of Two Optimized Multiplexed Serologic Assays for the 9-Valent Human Papillomavirus Vaccine Types
    Nolan, Katrina M.
    Seaton, Brent
    Antonello, Joseph
    Zhang, Yuhua
    Cook, Lauren
    Delfino, Krystyn
    Rubinstein, Leonard J.
    Cheon, Kyeongmi
    Luxembourg, Alain
    Dubeya, Sheri
    MSPHERE, 2023, 8 (02)
  • [29] US Primary Care Clinics' Experiences During Introduction of the 9-Valent HPV Vaccine
    Kornides, Melanie L.
    Calo, William A.
    Heisler-MacKinnon, Jennifer A.
    Gilkey, Melissa B.
    JOURNAL OF COMMUNITY HEALTH, 2018, 43 (02) : 291 - 296
  • [30] Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
    André B. Kind
    Andrew Pavelyev
    Smita Kothari
    Nadia El Mouaddin
    Aurélie Schmidt
    Edith Morais
    Patrik Guggisberg
    Florian Lienert
    BMC Public Health, 20